PneumaCare Ltd

PneumaCare Ltd is a biotechnology startup based in Cambridge, UK, and is a pioneer in Structured Light Plethysmography (SLP) technology. The company provides clinicians with revolutionary non-contact respiratory monitoring systems through its Thora-3Di® product family. This technology offers richer information on a broader patient population without the need for direct contact, reducing the risk of infection and instrument running costs. PneumaCare®'s proprietary SLP technology has diverse applications, including in clinics, pre- and post-operative assessments, drug testing, and device development, with potential expansion into home care, neonatal, critical care, and rehabilitation applications. In 2011, PneumaCare® received recognition, winning the overall Best Business Proposition and the Best Business Proposition in the Respiratory Category at the 2011 Medical Futures Innovations Awards. The company has obtained CE mark approval for its lead product, Thora-3Di®, and has appointed European distributors. Additionally, the company has applied for FDA approval. PneumaCare® received a £1.00M Venture Round investment on 30 October 2013, with investment from Cambridge Angels, Charterhouse Capital Partners, Cambridge Capital Group, Sud Investments, and Torteval Investments. This investment signifies confidence in PneumaCare®'s innovative approach to respiratory diagnostics and monitoring, as well as its potential for further growth and impact in the healthcare industry.